RP5063 Hydrochloride
| Code | Size | Price |
|---|
| TAR-T24736-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T24736-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T24736-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
RP5063 Hydrochloride is a modulator of multimodal serotonin receptors.
CAS:
1708960-04-6
Formula:
C22H26Cl3N3O3
Molecular Weight:
486.82
Purity:
0.98
SMILES:
Cl.Clc1cccc(N2CCN(CCCCOc3ccc4OCC(=O)Nc4c3)CC2)c1Cl
References
1. Bhat L, Hawkinson J, Cantillon M, Reddy DG, Bhat SR, Laurent CE, Bouchard A, Biernat M, Salvail D. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model. Eur J Pharmacol. 2018 Feb 14. pii: S0014-2999(18)30096-7. doi: 10.1016/j.ejphar.2018.02.017. [Epub ahead of print] PubMed PMID: 29453947.
2. Cantillon M, Bhat L. Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh. Schizophr Res. 2018 Jan 21. pii: S0920-9964(17)30569-8. doi: 10.1016/j.schres.2017.09.010. [Epub ahead of print] PubMed PMID: 29395606.
3. Cantillon M, Ings R, Bhat L. Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients. Clin Transl Sci. 2017 Nov 8. doi: 10.1111/cts.12518. [Epub ahead of print] PubMed PMID: 29119704.
4. Aboraya A. Concerns about the design, analyses, and findings of the trial of dopamine serotonin stabilizer RP5063 by Cantillon and colleagues. Schizophr Res. 2017 Aug 25. pii: S0920-9964(17)30508-X. doi: 10.1016/j.schres.2017.08.034. [Epub ahead of print] PubMed PMID: 28847613.